Treatment of cancer with a novel anti-IL13 monoclonal antibody
US7674459B2 · kind B2 · utility
35Cited by
15References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 23, 2004 |
| Grant date | Mar 9, 2010 |
| Priority date | — |
| Expiry date | May 29, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the treatment of IL13 dependent neoplastic disorders comprising the administration of novel anti-IL13 antibodies, The invention also includes diagnosing such tumors or cancer using the antibodies of the present invention to detect overexpression of IL13 in the patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.